文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Trastuzumab deruxtecan in patients with active brain metastases from HER2-positive/low metastatic breast cancer: a retrospective multicenter real-world study.

作者信息

Duan Fangfang, Hua Xin, Lu Wei, Gui Xingxing, Xie Jingdun, Wang Xudong, Ma Yuyu, Zhai Wenyu, Xia Wen

机构信息

State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.

Department of Anesthesiology, Sun Yat-sen University Cancer Center, Guangzhou, China.

出版信息

Breast Cancer Res. 2025 Jul 21;27(1):135. doi: 10.1186/s13058-025-02088-5.

DOI:10.1186/s13058-025-02088-5
PMID:40691796
Abstract
摘要

相似文献

[1]
Trastuzumab deruxtecan in patients with active brain metastases from HER2-positive/low metastatic breast cancer: a retrospective multicenter real-world study.

Breast Cancer Res. 2025-7-21

[2]
Trastuzumab Deruxtecan in Previously Treated HER2-Low Metastatic Breast Cancer: Real-World Multicentric Study in the Portuguese Population.

Cancers (Basel). 2025-6-9

[3]
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis.

Cancer Treat Rev. 2025-2

[4]
Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer.

ESMO Open. 2025-6-17

[5]
Prognostic index for predicting outcomes of trastuzumab deruxtecan in HER2 expressing metastatic breast cancer: a real-world multicenter study.

Oncologist. 2025-8-4

[6]
Long Durable Response With Trastuzumab Deruxtecan Monotherapy in a Triple-Negative Metastatic Breast Cancer Patient With Human Epidermal Growth Factor Receptor 2 Mutation: A Long-Term Follow-Up and Literature Review.

J Med Cases. 2025-6-16

[7]
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.

Lancet Oncol. 2023-7

[8]
Brain Metastases From HER2 Breast Cancer That Achieved Complete Response With Trastuzumab Deruxtecan Without Any Local Treatment.

Cureus. 2025-5-29

[9]
Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report.

Int J Womens Health. 2024-7-29

[10]
Long-term survival in a patient with brain metastases and leptomeningeal disease of breast cancer: a case report of a patient receiving trastuzumab-deruxtecan.

Arch Gynecol Obstet. 2025-7-8

本文引用的文献

[1]
TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases.

Future Oncol. 2025-4

[2]
Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan.

NPJ Precis Oncol. 2025-1-22

[3]
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.

Nat Med. 2024-12

[4]
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases.

Ann Oncol. 2024-12

[5]
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases.

Neuro Oncol. 2024-12-5

[6]
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.

Breast Cancer. 2024-9

[7]
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.

ESMO Open. 2024-5

[8]
"Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper".

Breast. 2024-8

[9]
Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial.

JAMA Oncol. 2024-3-1

[10]
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM).

NPJ Breast Cancer. 2023-10-11

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索